Once the Nasdaq delisting on Form 25 becomes effective, 23andMe intends to file a Form 15 to deregister with the SEC. About 23andMe 23andMe is a genetics-led consumer healthcare and biotechnology ...

Teva Pharmaceutical Industries Ltd., and Biolojic Design Ltd. ("Biolojic"), a biotechnology company using computational biology and artificial intelligence to design next generation, multifunctional ...

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has been named Best Managed Company in its anniversary year for the sixth time in a row. For 75 years, the ...

Regeneron has moved closer to a regulatory ... Squibb/bluebird bio’s Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s Carvykti (ciltacabtagene autoleucel) – that have shown ...

On 23 March 2025, the direct-to-consumer genetic testing company 23andMe filed a voluntary Chapter 11 petition in a US bankruptcy court.1 The objective of this bankruptcy is to sell the company ...

Despite announcing last month that it wouldn't pursue a full gaming license, Las Vegas Sands, which owns the lease to the ...

The next-gen immunotherapies market is evolving with biotech advances, rising cancer cases, new therapies, funding, and ...

BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data from select pipeline candidates across the Company's diversified oncology portfolio ...